Moderna's experimental vaccine that nearly halves the risk of skin cancer returning in high-risk patients is one step closer to becoming an approved treatment.
The shot, called Intismeran, is combined with Keytruda - an immunotherapy drug used to treat cancer made by pharmaceutical giant Merck - and slashes the risk of death and melanoma returning by 49 percent.
Intismeran met both its clinical trial goals of reducing cancer recurrence and preventing tumors from spreading to other parts of the body, according to interim results from its phase 3 trial released on Wednesday.
This is the first positive late-stage trial for an mRNA cancer vaccine, and also the first to show that adding the shot to Keytruda worked better than the immunotherapy drug alone.
Read Full Article Here